Pages that link to "Q26830509"
Jump to navigation
Jump to search
The following pages link to Immune Checkpoint Blockade in Cancer Therapy (Q26830509):
Displaying 50 items.
- The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics (Q26738677) (← links)
- The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis (Q26740280) (← links)
- Aptamers: A Feasible Technology in Cancer Immunotherapy (Q26740303) (← links)
- Psychological side effects of immune therapies: symptoms and pathomechanism (Q26741695) (← links)
- Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting (Q26742012) (← links)
- The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines (Q26764792) (← links)
- Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition (Q26766419) (← links)
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issues (Q26768641) (← links)
- Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role (Q26769734) (← links)
- Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review (Q26770716) (← links)
- Influence of immunoglobulin isotype on therapeutic antibody function (Q26772080) (← links)
- Current status of immunotherapy (Q26773314) (← links)
- Bacille-Calmette-Guerin non-responders: how to manage (Q26773679) (← links)
- Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies (Q26775034) (← links)
- Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis (Q26775460) (← links)
- Muscle-invasive urothelial bladder cancer: an update on systemic therapy (Q26775780) (← links)
- Overview of current immunotherapeutic strategies for glioma (Q26776345) (← links)
- Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles (Q26777403) (← links)
- Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis (Q26778025) (← links)
- Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling (Q26781643) (← links)
- How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)? (Q26785554) (← links)
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia (Q26785828) (← links)
- Immunotherapy of Childhood Sarcomas (Q26795369) (← links)
- Relevance of tumor-infiltrating lymphocytes in breast cancer (Q26795598) (← links)
- Perspectives in the treatment of pancreatic adenocarcinoma (Q26797248) (← links)
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers (Q27853176) (← links)
- Opportunities for immunotherapy in microsatellite instable colorectal cancer (Q28066110) (← links)
- Aptamers: A New Technological Platform in Cancer Immunotherapy (Q28068981) (← links)
- Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment (Q28069424) (← links)
- A perspective on anti-EGFR therapies targeting triple-negative breast cancer (Q28069867) (← links)
- Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last? (Q28078774) (← links)
- The interplay of immunotherapy and chemotherapy: harnessing potential synergies (Q28081893) (← links)
- Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy (Q28082914) (← links)
- Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy (Q28083766) (← links)
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma (Q28088496) (← links)
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports (Q28553328) (← links)
- Immunotherapy for metastatic renal cell carcinoma (Q30234458) (← links)
- Cancer immunotherapy: how low-level ionizing radiation can play a key role (Q30235014) (← links)
- Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. (Q30244608) (← links)
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination (Q30251438) (← links)
- Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. (Q30360210) (← links)
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors (Q33437383) (← links)
- Immunotherapy in hematologic malignancies: past, present, and future (Q33593865) (← links)
- Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer (Q33654352) (← links)
- Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8 T cells (Q33686036) (← links)
- Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab (Q33704061) (← links)
- Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents (Q33704284) (← links)
- A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer (Q33738937) (← links)
- A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy (Q33769203) (← links)
- Immunotherapeutic approaches for hepatocellular carcinoma (Q33779723) (← links)